Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel Oger

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Journal of Neurology|December 14, 2004
Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosisHelen Tremlett, Joel Oger
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 18, 2015
An update on laboratory diagnosis in myasthenia gravisJoel Oger, Hans Frykman
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 21, 2010
Where are we going with drugs to treat MS? Will cost continue to increase?Joel Oger, Mona AlKhawajah
Nature Clinical Practice. Neurology|August 26, 2006
Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?Joel Oger, Ebrima Gibbs
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 5, 2015
An update on laboratory diagnosis in myasthenia gravisJoel Oger, Hans Frykman
Multiple Sclerosis International|November 19, 2011
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Mona Alkhawajah, Joel Oger
Journal of Neuroimmunology|September 11, 2007
The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patientsEbrima Gibbs, Joel Oger
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|April 23, 2013
DMDs are an essential issue but are they the only issue in MS treatment?Saeed Shahbeigi, Joel Oger
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|October 22, 2008
A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patientsEbrima Gibbs, Joel Oger
Drugs & Aging|September 14, 2015
Treatment of Myasthenia Gravis in the AgedNuha M Alkhawajah, Joel Oger
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Journal of Neurology|December 14, 2004
Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosisHelen Tremlett, Joel Oger
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 18, 2015
An update on laboratory diagnosis in myasthenia gravisJoel Oger, Hans Frykman
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|May 21, 2010
Where are we going with drugs to treat MS? Will cost continue to increase?Joel Oger, Mona AlKhawajah
Nature Clinical Practice. Neurology|August 26, 2006
Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?Joel Oger, Ebrima Gibbs
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 5, 2015
An update on laboratory diagnosis in myasthenia gravisJoel Oger, Hans Frykman
Multiple Sclerosis International|November 19, 2011
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Mona Alkhawajah, Joel Oger
Journal of Neuroimmunology|September 11, 2007
The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patientsEbrima Gibbs, Joel Oger
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|April 23, 2013
DMDs are an essential issue but are they the only issue in MS treatment?Saeed Shahbeigi, Joel Oger
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|October 22, 2008
A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patientsEbrima Gibbs, Joel Oger
Drugs & Aging|September 14, 2015
Treatment of Myasthenia Gravis in the AgedNuha M Alkhawajah, Joel Oger
Pageof 7